Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Funapide - Flexion Therapeutics

Next Previous
Drug Profile

Funapide - Flexion Therapeutics

Alternative Names: FX 301; PCRX-301; TV 45070; XEN-402; XPF 002; XPF-001

Latest Information Update: 11 Mar 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Xenon Pharmaceuticals
  • Developer Flexion Therapeutics; Teva Pharmaceutical Industries; Xenon Pharmaceuticals
  • Class Benzodioxoles; Fluorobenzenes; Furans; Indoles; Non-opioid analgesics; Small molecules; Spiro compounds; Vascular disorder therapies
  • Mechanism of Action Nav1.7 voltage-gated sodium channel inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Erythromelalgia
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Dental pain; Erythromelalgia; Musculoskeletal pain; Neuropathic pain; Pain; Postherpetic neuralgia; Postoperative pain

Most Recent Events

  • 30 Sep 2022 Discontinued - Phase-I for Postoperative pain in USA (Parenteral)
  • 30 Sep 2022 Discontinued - Phase-II for Postherpetic neuralgia in USA (Topical)
  • 30 Mar 2022 Flexion Therapeutics completes a phase Ib proof of concept trial for Postoperative pain in USA (Parenteral)(NCT04826328)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top